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In tegumentary leishmaniasis caused by Leishmania braziliensis, there is evidence that increased produc-
tion of IFN-c, TNF-a and absence of IL-10 is associated with strong inﬂammatory reaction and with tissue
destruction and development of the lesions observed in cutaneous leishmaniasis (CL) and mucosal
leishmaniasis (ML). We evaluate the role of regulatory cytokines and cytokine antagonists in the down-
regulation of immune response in L. braziliensis infection. Peripheral blood mononuclear cells from CL and
ML were stimulated with soluble Leishmania antigen in the presence or absence of regulatory cytokines
(IL-10, IL-27 and TGF-b) or antagonists of cytokines (a-TNF-a and a-IFN-c). Cytokines production (IL-10,
IL-17, TNF-a and IFN-c) was measured by ELISA. IL-10 and TGF-b downmodulate TNF-a and IL-17
production, whereas IL-27 had no effect in the production of TNF-a, IFN-c and IL-17 in these patients.
Neutralization of TNF-a decreased IFN-c level and the neutralization of IFN-c decreased TNF-a level
and increased IL-10 production. This study demonstrate that IL-10 and TGF-b are cytokines that appear
to be more involved in modulation of immune response in CL and ML patients. IL-10 might have a pro-
tective role, since the neutralization of IFN-c decreases the production of TNF-a in an IL-10-dependent
manner.
 2014 The Authors. Published by Elsevier Ltd. Open access under CC BY-NC-ND license. 1. Introduction
Type 1 immune responses and the IFN-c and TNF-a produced
by these responses are important to prevent growth of intracellular
microbial agents and control dissemination of infections with
intracellular agents like Leishmania [1,2]. However, in tegumentary
leishmaniasis caused by Leishmania braziliensis, there is evidence
that increased production of IFN-c and TNF-a is associated with in-
creased inﬂammatory reaction and development of cutaneous and
mucosal ulcers, despite low numbers of detectable parasites in le-
sions using conventional techniques [3,4]. Moreover, lymphocyte
activation, proliferation and cytokine secretion upon stimulation
with Leishmania antigens are higher in mucosal leishmaniasis
compared with cutaneous leishmaniasis [1,5], which corresponds
with the severity of tissue destruction in mucosal leishmaniasis.IL-17 is also expressed at a higher level in the peripheral blood
and tissues of mucosal and cutaneous leishmaniasis patients [6].
IL-17 and neutrophils have been associated with pathology in mice
infected with L. braziliensis and in human leishmaniasis [7,8]. We
have previously shown impairment of the ability of the regulatory
cytokine IL-10 to downmodulate inﬂammatory cytokine produc-
tion in cutaneous and mucosal leishmaniasis [9]. However, the role
of other cytokines in modulating IFN-c and TNF-a remains to be
determined. TGF-b is known to decrease lymphocyte proliferation
and cytokine production [10–12]. While IL-27 may induce lympho-
cyte activation during the initial steps of the immune response
[13], it has an important regulatory function to prevent inﬂamma-
tion and subsequent tissue damage in the late phase of the im-
mune response [14].
In the majority of diseases in which type 1 immune responses
play a role in pathology, the key cytokines are TNF-a and IFN-c
[15]. In CL and ML, although antimony therapy failure occurs in
up to 35% of cases [16] the use of pentoxifylline, a TNF-a inhibitor
that modulates IFN-c production, has resulted in an increased rate
of cure. Moreover, pentoxifylline plus antimony therapy reduces
the healing time of cutaneous and mucosal ulcers and cures CL
and ML patients that are refractory to antimony treatment alone
[17–19]. Therefore, appropriate modulation of the immune
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with the exaggerated Th1 immune response observed in human
leishmaniasis.
The aim of the present study was to better understand the cyto-
kine network during L. braziliensis infection and to identify mole-
cules associated with potentiating of the inﬂammatory response
or downregulating the inﬂammatory response. The identiﬁcation
of target molecules that may downregulate the inﬂammatory re-
sponse may help to attenuate pathology in cutaneous and mucosal
leishmaniasis.2. Materials and methods
2.1. Study population
Forty CL patients and eighteen ML patients recruited at the
health center of Corte de Pedra, an endemic area of L. braziliensis
transmission that is located in the state of Bahia, Brazil, were en-
rolled in this study. Only those CL patients with a single typical
ulcerative skin lesion of 1–3 months in duration without evidence
of mucosal involvement and without a history of previous therapy
were enrolled in this study. Mucosal leishmaniasis patients pre-
sented lesions in nasopharyngeal regions. The diagnosis of CL and
ML was performed by detecting parasites from culture aspirates or
histopathology or by the presence of a typical CL or ML lesion plus
a positive delayed-type hypersensitivity (DTH) reaction to a L. bra-
ziliensis antigen [20]. All participants provided informed consent,
and the study followed the guidelines of the Ethical Committee
of the Federal University of Bahia.2.2. Cell cultures
Peripheral blood mononuclear cells (PBMC) were separated
from heparinized venous blood by Ficoll-Hypaque gradient centri-
fugation. The cells were cultured in RPMI 1640 (Life Technologies
GibcoBRL, Grand Island, NY, USA) containing 10% human AB serum
(Sigma, St. Louis, MO, USA), HEPES and antibiotics at a concentra-
tion of 3  106 cells/mL. These cells were plated in 24-well ﬂat bot-
tom microtiter plates (Falcon; Becton Dickinson, Lincoln Park, NJ,
USA) and stimulated with media alone (unstimulated), 5 lg/mL
of soluble Leishmania antigen (SLA) or with SLA and other speciﬁc
stimuli. To determine whether IL-27 downregulates IFN-c and
TNF-a production as well as to determine its effect on IL-10 pro-
duction, recombinant human IL-27 (rIL-27) (R&D Systems, Minne-
apolis, MN, USA) was added to PBMC cultures at 100 ng/mL. To
evaluate whether the neutralization of IFN-c decreases TNF-a,
anti-human IFN-c (R&D Systems, Minneapolis, MN, USA) was
added to PBMC cultures at a concentration of 100 lg/mL. The re-
sults neutralizing TNF-a on IFN-c production was evaluated by
adding anti-human TNF-a (R&D Systems, Minneapolis, MN, USA)
at 20 lg/mL to PBMC cultures. To determine if TGF-b altered
TNF-a and IL-17 production recombinant human TGF-b (rTGF-b1,
10 ng/mL) (R&D Systems, Minneapolis, MN, USA) were added to
PBMC cultures. The concentrations of cytokines or monoclonal
antibodies added to the cultures were determined after a dose–re-
sponse curve was generated in a limited number of patients and
the optimal concentration was chosen for suppression experiments
(data not shown).2.3. Cytokine production
Cell cultures were incubated at 37 C with 5% CO2 for 72 h or
96 h in the case of measuring IL-17 levels. IFN-c, TNF-a, IL-10
and IL-17 levels were determined in supernatants using thesandwich ELISA technique (BD Bioscience Pharmingen, San Jose,
CA, USA). The results are expressed in pg/mL.
2.4. Statistical analysis
Statistical analysis was performed with the Wilcoxon matched
pairs test using GraphPad Instat Software (GraphPad, San Diego,
CA, USA) and GraphPad Prism 5 Software (GraphPad, San Diego,
CA, USA). The results are expressed as medians (interquartile
range). Differences were considered to be statistically signiﬁcant
when P 6 0.05.3. Results
3.1. Clinical and immunological characteristics of cutaneous
leishmaniasis patients (CL) and mucosal leishmaniasis patients (ML)
As demonstrated in Table 1, there were no statistical differences
in age, gender, DTH, TNF-a, IL-17 and IL-10 levels between the two
groups (all > 0.05). However, the mean of IFN-c was found to be
signiﬁcantly higher in the mucosal leishmaniasis patients
(p < 0.05).
3.2. IL-10 and TGF-b downregulate TNF-a and IL-17 production by
cells from leishmaniasis patients
We have already shown a decreased ability of IL-10 to down-
regulate IFN-c in patients with ML [9]. The ability of IL-10 and
TGF-b to downregulate TNF-a and IL-17 production is shown in
Fig. 1. IL-10 downregulated TNF-a production in CL patients but
not in ML patients (Fig. 1a). In cells from CL patients, the median
level of TNF-a in cells stimulated with SLA was 1893 pg/mL (0–
7440 pg/mL), while stimulation with SLA and IL-10 resulted in
TNF-a levels of 280 pg/mL (0–6280 pg/mL) P < 0.0005. In cells from
ML patients, the concentration of TNF-a upon stimulation with SLA
was 1790 pg/mL (892–9173 pg/mL) and stimulation with SLA and
IL-10 did not decrease the level of TNF-a production, which was
1715 pg/mL (320–2526 pg/mL) (P > 0.05). IL-10 also had an inhib-
itory effect on IL-17 production in cells from both CL and ML pa-
tients (Fig. 1b). In cells from CL patients stimulated with SLA, IL-
17 levels were 28 pg/mL (0–680 pg/mL) and decreased to 0 pg/ml
(0–178 pg/mL) in cells stimulated with SLA plus IL-10 (P < 0.05).
In cells from ML, IL-10 also decreased IL-17 production in culture
stimulated with SLA from 58 pg/mL (0–141 pg/mL) in the absence
of IL-10 to 23 pg/mL (4–129 pg/mL) after addition of IL-10
(P < 0.05).
The activity of TGF-b was assessed to examine its effect on the
production of TNF-a and IL-17. TGF-b decreased TNF-a levels from
1320 pg/mL (15–7440 pg/mL) to 367 pg/mL (0–7100 pg/mL) in
cells from CL patients (P < 0.0005) and from 2080 pg/mL
(110–9173 pg/mL) to 117 pg/mL (0–8127 pg/mL) in cells from ML
patients (P < 0.05) (Fig. 2a). The addition of TGF-b to the culture de-
creased IL-17 production from 36 pg/mL (1–680 pg/mL) to 15 pg/
mL (0–382 pg/ml) in cells from CL patients (P < 0.005) but had no
effect in cells from ML patients, as IL-17 production was 173 pg/
mL (93–305 pg/mL) following SLA treatment and 48 pg/mL (0–
263 pg/mL) following SLA plus TGF-b (Fig. 2b) (P > 0.05).
IL-27 was not able to suppress TNF-a production by cells from
leishmaniasis patients: In addition to its role in stimulating a Th1-
type immune response, IL-27 is known to attenuate inﬂammatory
cytokine production [21,22]. In the present study, IL-27 did not
suppress IFN-c production in cells from CL patients, which was
2203 pg/mL following SLA stimulation (105–12,560 pg/mL) and
2670 pg/mL (0–9150 pg/mL) following SLA plus IL-27 stimulation
(P < 0.05). IL-27 also failed to downregulate the secretion of this
Table 1
Clinical and immunological characteristics of cutaneous leishmaniasis patients (CL) and mucosal leishmaniasis patients (ML).
Cutaneous leishmaniasis (n = 40) Mucosal leishmaniasis (n = 18) p Valuea
Age (years) 31.4 ± 13.7 38.3 ± 15.3 <0.05
Gender (% of male) 29 (72%) 9 (50%) <0.05
DTH reaction to a Leishmania antigen (mm) 17  16 19  17 <0.05
IFN-c (pg/ml) 3960 ± 729 5162 ± 1688 >0.05
TNF-a (pg/ml) 1695 ± 232 2285 ± 539 <0.05
IL-17 (pg/ml) 75 ± 23 98 ± 22 <0.05
IL-10 (pg/ml) 176 ± 36 78 ± 24 >0.05
Values are displayed as mean ± SEM; DTH: delayed-type hypersensitivity.
a Tests of signiﬁcance between groups were based on Mann Whitney test.
Fig. 1. Modulator activity of IL-10 in the production of TNF (A) and IL-17 (B) by cells
from patients with tegumentary leishmaniasis: PBMC from patients with CL and ML
were stimulated with SLA (5 lg/ml) in the presence or not of IL-10 (10 ng/ml). The
production of TNF (A) and IL-17 (B) was evaluated by ELISA. Statistical analysis was
performed by Wilcoxon matched pairs test. (*p < 0.05).
Fig. 2. Modulator activity of TGF-b in the production of cytokines by cells from
patients with tegumentary leishmaniasis: PBMC from patients with CL and ML were
stimulated with SLA (5 lg/ml) in the presence or not of TGF-b (10 ng/ml). The
production of TNF (A), IL-17 (B) and IFN-c (C) was evaluated by ELISA. Statistical
analysis was performed by Wilcoxon matched pairs test. (*p < 0.05).
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mL (0–24,880 pg/mL) following SLA stimulation and 1785 pg/mL
(65–13,106 pg/mL) following SLA plus IL-27 stimulation
(P > 0.05). Moreover, the addition of IL-27 did not change TNF-a
production from cultured cells (data not shown).
IL-27 has been shown to induce IL-10 production by human
CD4+ T cells [23]. In the present study, the addition of IL-27 to
PBMC from CL and ML patients did not enhance IL-10 production
by cells from CL patients, as the observed IL-10 production was
84 pg/mL (2–925 pg/mL) following SLA stimulation and 98 pg/mL
(10–864 pg/mL) following SLA and IL-27 stimulation. Similar re-
sults were observed using cells from ML patients, as IL-10 levels
were 43 pg/mL (8–130 pg/mL) following SLA stimulation and
77 pg/mL (32–308 pg/mL) following SLA plus IL-27 stimulation
(P > 0.05).3.3. Neutralization of TNF-a inhibits IFN-c production and does not
induce IL-10 production
We have already shown that macrophages contribute to the
production of TNF-a in human tegumentary leishmaniasis [9]
and that this cytokine can activate of antigen presenting cells to
thereby enhance the ability of CD4+ T cells to produce IFN-c. To as-
sess this cytokine production network, we stimulated cells from CL
and ML patients with SLA in the presence or absence of an anti-
TNF-a monoclonal antibody (mAb) and measured the production
of IFN-c (Fig. 3). Neutralization of TNF-a downregulated IFN-c pro-
duction from 2820 pg/ml (1120–10,280) following SLA treatment
alone to 2440 pg/ml (250–9050) following mAb addition in cells
from CL patients (Fig. 3a), p < 0.005. Also, TNF-a neutralization re-
duced IFN-c production from 5687 pg/ml (1040–17,160) following
SLA stimulation to 3255 pg/ml (80–13,420) following SLA plus
mAb stimulation in cells from ML patients (Fig. 3b), p < 0.05. Neu-
tralization of TNF-a did not modify IL-10 production (data not
shown).
Fig. 3. Neutralization of TNF-a affect IFN-c production by cells from patients with tegumentary leishmaniasis: PBMC from patients with CL and ML were stimulated with SLA
(5 lg/ml) in the presence or not of anti-TNF antibody (20 lg/ml). The production of IFN-c was evaluated by ELISA. Statistical analysis was performed by Wilcoxon matched
pairs test. (*p < 0.05; **p < 0.0005).
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10 production
As the overproduction of IFN-c could be involved in the high le-
vel of TNF-a production, we investigated the effect of neutralizing
IFN-c on TNF-a production by cells from patients with CL and ML.
Neutralization of IFN-c decreases TNF-a production in cells from
CL and ML patients (Fig. 4). In cultures stimulated with SLA, the
median level of TNF-a production was 802 pg/mL (0–9173 pg/
mL), while the addition of anti-IFN-c resulted in a TNF-a level of
494 pg/mL (0–2210 pg/mL) in cells from CL patients (Fig. 4a),
P < 0.05. In cells from ML patients, the level of TNF-a production
was 2800 pg/mL (110–9173 pg/mL) without anti-IFN-c and
401 pg/mL (100–2309 pg/mL) after IFN-c neutralization (Fig. 4b),
P < 0.05. The neutralization of IFN-c increased IL-10 production
as well. In cells from CL patients, the median level of IL-10 produc-
tion was 107 pg/mL (31–925 pg/mL) and after neutralization of
IFN-c, the level of IL-10 was 1001 pg/mL (51–1365 pg/mL). In cells
from ML patients, the IL-10 level was 92.5 pg/mL (12–265 pg/mL)
when cells were stimulated with SLA and 671 pg/mL (51–886 pg/
mL) after neutralization of IFN-c, P < 0.005 and P < 0.05, respec-
tively (Fig. 5a and b).Fig. 4. Neutralization of IFN-c affect TNF-a production by cells from patients with tegum
with SLA (5 lg/ml) in the presence or not of anti-INF-c antibody (20 lg/ml). The producti
matched pairs test. (*p < 0.05).4. Discussion
In this study, we have demonstrated that the modulation of the
inﬂammatory response in patients with tegumentary leishmania-
sis caused by L. braziliensis is associated with increased production
of IL-10. There are multiple studies that have shown that a strong
Th1-type immune response including the production of the proin-
ﬂammatory cytokines IFN-c and TNF-a and decreases in produc-
tion of IL-10 or the IL-10 receptor leads to an exaggerated
inﬂammatory response that is responsible for lesion development
in CL and ML patients [9,24,25]. In this study, it was shown that
while IL-10 and TGF-b modulate the production of TNF-a and IL-
17, IL-27 did not have an important role in modulating the produc-
tion of inﬂammatory cytokines. Moreover, we showed that IFN-c
plays an important role in the maintenance of inﬂammation as
neutralization of IFN-c decreased TNF-a production and increased
the production of IL-10.
IL-10 is known to have anti-inﬂammatory proprieties and to be
necessary to control the strong inﬂammatory response that may
follow a tissue immune response [26]. IL-10 play a key role in
downregulating IFN-c production in human visceral leishmaniasis
[27–29], but studies have shown that this cytokine does not alterentary leishmaniasis: PBMC from patients with CL (A) and ML (B) were stimulated
on of TNF-awas evaluated by ELISA. Statistical analysis was performed by Wilcoxon
Fig. 5. Neutralization of IFN-c increase IL-10 production by cells from patients with tegumentary leishmaniasis: PBMC from patients with CL (A) and ML (B) were stimulated
with SLA (5 lg/ml) in the presence or not of anti-INF-c antibody (20 lg/ml). The production of IL-10 was evaluated by ELISA. Statistical analysis was performed by Wilcoxon
matched pairs test. (*p < 0.005; **p < 0.05).
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have shown that IL-10 can modulate the production of TNF-a by
cells from CL patients, resulting in 85% suppression, but that this
cytokine does not have the same effect on cells from ML patients.
The regulatory activity of IL-10 depends on the expression of its
receptor [30]. Previous studies have shown that ML patients pro-
duce more TNF-a and less IL-10 compared with CL patients [9].
One possible explanation for the decreased ability of IL-10 modu-
late the production of TNF-a in ML patients is the observation that
cells from mucosal lesions express less IL-10 receptor when com-
pared to cells from cutaneous lesions [24].
An important ﬁnding in this study is the observation that IL-10
decreases the production of IL-17 by cells from CL and ML patients.
Although IL-17 is involved in the defense against several intracel-
lular agents [31,32], this cytokine contributes to inﬂammation by
inducing the recruitment of neutrophils and the production of var-
ious inﬂammatory mediators such as IL-1, IL-6, and TNF-a [33].
PBMC from patients with CL and ML produce more IL-17 than do
cells from uninfected individuals, and this cytokine is also present
in the lesions of these leishmaniasis patients [6,8], indicating that
it may participate in the tissue destruction observed in this disease.
The observation that IL-10 decreases the production of IL-17 by
cells from CL and ML patients supports other studies that show
that IL-10 can regulate IL-17 production in other inﬂammatory dis-
eases such as colitis and chronic pulmonary Mycobacterium avium
infection.
TGF-b is another cytokine that is able to regulate the inﬂamma-
tory immune response by suppressing the differentiation of CD4+
effector cells, inducing the conversion of naïve T cells into Treg
cells, inhibiting the production of IL-2 and IFN-c and suppressing
the activity of macrophages, dendritic cells and natural killer
(NK) cells [34]. In a human cutaneous leishmaniasis system, the
in vitro addition of TGF-b to cultures of PBMC from ML and CL pa-
tients did not inhibit IFN-c production in response to leishmania
antigen but did inhibit the production of IFN-c by cells from
healthy individuals stimulated with PPD by 47% [9]. In this study
however, TGF-b abolished the TNF-a production by cells from pa-
tients with CL and ML. The inhibitory effect of TGF-b on Th1 cells is
minimal in activated T cells, where there is decreased expression of
TGF-b receptors, and this expression is IL-10 dependent [35]. The
previous observation that the levels of IFN-c are greater than the
levels of TNF-a in these patients and that the production of IL-10
is low or absent in these patients [9] may explain why TGF-b has
a greater effect on the production of TNF-a than on IFN-c produc-
tion in patients with CL. Although controversial, it has been docu-
mented that IL-6 and TGF-b induce the production of IL-17 bynaïve T cells [33]. However, the results presented in this study sug-
gest that TGF-b may be a modulator of IL-17 production in cells
from patients with CL. As the cells from these patients have previ-
ously been activated and are being restimulated in vitro by leish-
mania antigen, TGF-b may have more of a modulatory role than a
role as an inducer of IL-17 in this system.
Initial studies of the biology of IL-27 provide evidence for the
role of this cytokine in initiating the Th1-type immune response
[13,36]. However, subsequent studies have indicated that IL-27
has a wide inhibitory role on Th1 cells, preventing the immunopa-
thology caused by this class of T cells [14,37]. Our results indicate
that IL-27 does not affect the production of IFN-c, TNF-a or IL-17
by the cells from patients with CL and ML. The anti-inﬂammatory
effects of IL-27 are partially due to production of IL-10 [23,38]. The
addition of IL-27 to PBMC cultures from patients with CL and ML
did not interfere with the production of IL-10 by these cells, con-
ﬁrming that IL-27 did not have an effect on regulating the strong
inﬂammatory response observed in human cutaneous leishmania-
sis in this study.
It has been observed that macrophages from patients with CL
and ML that are infected with L. braziliensis produce large amounts
of TNF-awhen compared with macrophages from individuals with
subclinical infection by L. braziliensis [39]. As this initial production
of TNF-a by macrophages during the innate immune response
could contribute to the exaggerated production of IFN-c from the
T cells of these patients, neutralization of TNF-a could interfere
with the secretion of IFN-c. In this study, it was observed that
the inhibition of TNF-a diminished the production of IFN-c, but
did not interfere with the production of IL-10 by PBMC from pa-
tients with ML and CL. These results together with the initial data
that demonstrated that treatment with antimony associated with
pentoxifylline, an inhibitor of TNF-a, cures patients refractory to
antimony and accelerates the healing of these patients [18,19] sug-
gest that TNF-a may contribute to the exaggerated production of
IFN-c and tissue destruction observed in this disease.
However, the inhibition of IFN-c signiﬁcantly decreased the
production of TNF-a by PBMC from patients with CL and ML. Thus,
the production of IFN-c by Th1 cells could also stimulate the
production of TNF-a by these cells. The decrease of TNF-a observed
in this study was accompanied by an increase in the production of
IL-10 by these patients. This ﬁnding is important as IL-10 has been
shown have a protective role in some inﬂammatory diseases
[38,40,41].
In conclusion, together, these results indicate that in tegumen-
tary leishmaniasis caused by L. braziliensis, IFN-c and TNF-a are the
main cytokines involved in the tissue damage observed in this
132 W.N. Oliveira et al. / Cytokine 66 (2014) 127–132disease and that IL-10 may have a protective role. Further studies
are needed to elucidate the rationale for use of IL-10 therapy in
human tegumentary leishmaniasis.
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